Age Labs AS, established in 2017 in Norway, focuses on discovering biomarkers for early detection of age-related diseases through epigenetic analysis of immune cells. Founded by experts in science, medicine, and engineering, the company leverages its expertise in aging and genetics to develop predictive algorithms for assessing disease risk. By analyzing DNA methylation in immune cells with machine learning, Age Labs utilizes a vast collection of biosamples from public and private biobanks worldwide. Their proprietary EPIPHANY platform generates detailed epigenetic reports, linking disease mechanisms with drug effects, supporting researchers in drug development and clinical applications for patient care.